Conjugated Linoleic Acid for Weight Control
Are there any side effects or interactions?
Overweight volunteers who took 4.5 grams of CLA
per day for one year had an increase in their blood levels of lipoprotein(a), a risk factor
for heart disease.9 While the significance of this change is not certain, it is
possible that long-term use of CLA could increase the risk of developing heart disease.
In a double-blind study of people with type 2
diabetes, supplementing with 3 grams of CLA per day for eight weeks significantly
increased blood glucose levels by 6.3% and decreased insulin sensitivity.10 A
reduction in insulin sensitivity was also seen in a study of overweight men without diabetes
after treatment with 3 grams of CLA per day for three months,11 although in a study
of young sedentary men, 4 grams of CLA per day for eight weeks improved insulin
sensitivity.12 Thus, although the studies are conflicting, CLA may be harmful for
some people who have, or are at risk of developing, diabetes. One unpublished human trial
reported isolated cases of gastrointestinal upset.13
At the time of writing, there were no well-known drug interactions
with conjugated linoleic acid.
References
1. Herbel BK, McGuire MK, McGuire MA, et al. Safflower oil consumption
does not increase plasma conjugated linoleic acid concentrations in humans. Am J Clin
Nutr 1998;67:332–7.
2. Thom E, Wadstein J, Gudmundsen O. Conjugated linoleic acid reduces
body fat in healthy exercising humans. J Int Med Res 2001;29:392–6.
3. Mougios V, Matsakas A, Petridou A, et al. Effect of supplementation
with conjugated linoleic acid on human serum lipids and body fat. J Nutr Biochem
2001;12:585–94.
4. Zambell KL, Keim NL, Van Loan MD, et al. Conjugated linoleic acid
supplementation in humans: effects on body composition and energy expenditure. Lipids
2000;35:777–82.
5. Riserus U, Berglund L, Vessby B. Conjugated linoleic acid (CLA)
reduced abdominal adipose tissue in obese middle-aged men with signs of the metabolic
syndrome: a randomised controlled trial. Int J Obes Relat Metab Disord
2001;25:1129–35.
6. Smedman A, Vessby B. Conjugated linoleic acid supplementation in
humans—metabolic effects. Lipids 2001;36:773–81.
7. Blankson H, Stakkestad JA, Fagertun H, et al. Conjugated linoleic acid
reduces body fat mass in overweight and obese humans. J Nutr
2000;130:2943–8.
8. Kreider RB, Ferreira MP, Greenwood M, et al. Effects of conjugated
linoleic acid supplementation during resistance training on body composition, bone density,
strength, and selected hematological markers. J Strength Cond Res
2002;16:325–34.
9. Gaullier JM, Halse J, Hoye K, et al. Conjugated linoleic acid
supplementation for 1 y reduces body fat mass in healthy overweight humans. Am J Clin
Nutr 2004;79:1118–25.
10. Moloney F, Yeow TP, Mullen A, et al. Conjugated linoleic acid
supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2
diabetes mellitus. Am J Clin Nutr 2004;80:887-95.
11. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11
conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and
proinflammatory markers in obese men. Am J Clin Nutr 2004;80:279–83.
12. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves
insulin sensitivity in young, sedentary humans. Med Sci Sports Exerc
2004;36:814–20.
13. Thom E. A pilot study with the aim of studying the efficacy and
tolerability of Tonalin CLA on the body composition in humans. Lillestrom, Norway: Medstat
Research Ltd., July 1997 [unpublished].